Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary-adrenal function

Growth hormone release-inhibiting hormone (GHR-IH) was administered to five patients with abnormal pituitary-adrenal function. There was immediate suppression by about 50% of ACTH levels in two patients who had undergone bilateral adrenalectomy because of Cushing's disease; one of them had Nels...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical endocrinology (Oxford) Vol. 5; no. 2; p. 187
Main Authors:	Benker, G, Hackenberg, K, Hamburger, B, Reinwein, D
Format:	Journal Article
Language:	English
Published:	England 01-03-1976
Subjects:	Adrenal Gland Diseases - blood Adrenocorticotropic Hormone - blood Adult Bromocriptine - pharmacology Ergolines - pharmacology Female Humans Hydrocortisone - blood Male Middle Aged Pituitary Diseases - blood Somatostatin - pharmacology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Growth hormone release-inhibiting hormone (GHR-IH) was administered to five patients with abnormal pituitary-adrenal function. There was immediate suppression by about 50% of ACTH levels in two patients who had undergone bilateral adrenalectomy because of Cushing's disease; one of them had Nelson's syndrome. Bromocryptine (2-5 mg) suppressed ACTH levels by 62-67% for more than 6 h in these patients. GHR-IH did not significantly influence cortisol secretion by an adrenal carcinoma and only slight changes were seen in two patients with Addison's disease. The possible therapeutic implications are discussed.
ISSN:	0300-0664
DOI:	10.1111/j.1365-2265.1976.tb02831.x